Keros Therapeutics’ (KROS) “Neutral” Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research report sent to investors on Friday morning,Benzinga reports.

KROS has been the topic of several other reports. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday. Wedbush reiterated an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $10.86 on Friday. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00. The stock has a market cap of $439.91 million, a PE ratio of -2.08 and a beta of 1.43. The stock has a fifty day moving average of $37.51 and a 200-day moving average of $47.36.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period in the previous year, the firm earned ($1.33) earnings per share. The firm’s quarterly revenue was up 4750.0% on a year-over-year basis. On average, sell-side analysts predict that Keros Therapeutics will post -4.74 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. FMR LLC boosted its position in Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the period. Alkeon Capital Management LLC lifted its stake in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. boosted its holdings in Keros Therapeutics by 6.3% during the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares during the period. Point72 Asset Management L.P. grew its position in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Finally, Holocene Advisors LP increased its stake in Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.